New Releases from NCBI BookshelfAbemaciclib (Verzenio): Therapeutic area: Adjuvant treatment of hormone receptor–positive, HER2-negative early breast cancer: Reimbursement Review [Internet].​Abemaciclib (Verzenio): Therapeutic area: Adjuvant treatment of hormone receptor–positive, HER2-negative early breast cancer: Reimbursement Review [Internet].